Actively Recruiting
A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
Led by Tarsus Pharmaceuticals, Inc. · Updated on 2026-05-01
700
Participants Needed
19
Research Sites
90 weeks
Total Duration
On this page
Sponsors
T
Tarsus Pharmaceuticals, Inc.
Lead Sponsor
P
PPD Development, LP
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is designed to evaluate the safety, tolerability, and pharmacokinetics of TP05 administered orally to healthy adult participants.
CONDITIONS
Official Title
A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy adults aged 18 to 70 years
- Able to provide written informed consent
- Willing and able to follow study procedures
- At high risk of tick exposure
- Use contraception according to local rules for men and women
You will not qualify if you...
- Prior use of TP05 or similar drugs in the past 12 months
- Known allergy to TP05 or related compounds
- Significant medical conditions interfering with participation
- Use of investigational drugs within 30 days before screening
- Previous Lyme disease vaccination including investigational vaccines
- Receiving long-term antibiotic treatment
- Received any immunization within 4 weeks before Day 1
- Pregnant or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 19 locations
1
Study Site
Pikesville, Maryland, United States, 21208
Actively Recruiting
2
Study Site
Brookline, Massachusetts, United States, 02445
Actively Recruiting
3
Study Site
Fall River, Massachusetts, United States, 02723
Not Yet Recruiting
4
Study Site
Minneapolis, Minnesota, United States, 55402
Actively Recruiting
5
Study Site
Marlboro, New Jersey, United States, 07746
Actively Recruiting
6
Study Site
Albany, New York, United States, 12205
Actively Recruiting
7
Study Site
Binghamton, New York, United States, 13905
Actively Recruiting
8
Study Site
Buffalo, New York, United States, 14217
Actively Recruiting
9
Study Site
East Syracuse, New York, United States, 13057
Actively Recruiting
10
Study Site
Middletown, New York, United States, 10941
Actively Recruiting
11
Study Site
New York, New York, United States, 10036
Actively Recruiting
12
Study Site
Rochester, New York, United States, 14609
Actively Recruiting
13
Study Site
Erie, Pennsylvania, United States, 16508
Actively Recruiting
14
Study Site
Hatboro, Pennsylvania, United States, 19040
Actively Recruiting
15
Study Site
Philadelphia, Pennsylvania, United States, 19107
Actively Recruiting
16
Study Site
Pittsburgh, Pennsylvania, United States, 15236
Actively Recruiting
17
Study Site
Pottstown, Pennsylvania, United States, 19464
Actively Recruiting
18
Study Site
West Chester, Pennsylvania, United States, 19380
Actively Recruiting
19
Study Site
Warwick, Rhode Island, United States, 02886
Actively Recruiting
Research Team
S
Study Director
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here